Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedAug 17, 2026
DataAggregated Company Financials
Companies53
  • 7D-1.4%
  • 3M2.3%
  • 1Y-2.1%
  • YTD7.1%

Over the last 7 days, the Pharma industry has dropped 1.4%, driven by Apotex Health declining 8.6%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 17 Aug 2026CA$21.9bCA$13.6b-CA$943,192,275.209.5x-23.2x1.6x
Wed, 15 Jul 2026CA$14.0bCA$10.6b-CA$1,727,215,105.109.8x-8.1x1.3x
Fri, 12 Jun 2026CA$14.6bCA$10.6b-CA$1,804,979,088.488.1x-8.1x1.4x
Sun, 10 May 2026CA$17.4bCA$11.3b-CA$1,391,269,740.9114.6x-12.5x1.5x
Tue, 07 Apr 2026CA$14.2bCA$11.4b-CA$1,657,405,027.4412.7x-8.6x1.3x
Thu, 05 Mar 2026CA$14.0bCA$11.2b-CA$1,804,366,150.3813.2x-7.8x1.3x
Sat, 31 Jan 2026CA$14.4bCA$11.2b-CA$1,972,282,610.8916.3x-7.3x1.3x
Mon, 29 Dec 2025CA$16.4bCA$11.2b-CA$1,934,890,119.0616.1x-8.5x1.5x
Wed, 26 Nov 2025CA$13.4bCA$11.4b-CA$1,930,907,058.1214.6x-6.9x1.2x
Fri, 24 Oct 2025CA$15.9bCA$11.3b-CA$2,038,424,469.5732.7x-7.8x1.4x
Sun, 21 Sep 2025CA$16.1bCA$11.2b-CA$2,028,829,168.5239.4x-7.9x1.4x
Tue, 19 Aug 2025CA$15.8bCA$11.8b-CA$2,550,311,028.3836.6x-6.2x1.3x
Thu, 17 Jul 2025CA$10.6bCA$11.7b-CA$2,542,179,845.5519.1x-4.2x0.9x
Sat, 14 Jun 2025CA$9.8bCA$11.6b-CA$2,505,293,273.5318.3x-3.9x0.8x
Mon, 12 May 2025CA$10.0bCA$11.9b-CA$2,536,992,379.8420.8x-3.9x0.8x
Wed, 09 Apr 2025CA$8.9bCA$12.3b-CA$2,623,778,179.5317.4x-3.4x0.7x
Fri, 07 Mar 2025CA$11.5bCA$12.3b-CA$2,637,532,520.8322.2x-4.4x0.9x
Sun, 02 Feb 2025CA$12.0bCA$12.3b-CA$2,397,744,121.5625.9x-5x1x
Tue, 31 Dec 2024CA$12.6bCA$12.1b-CA$2,410,883,218.1024.6x-5.2x1x
Thu, 28 Nov 2024CA$14.3bCA$11.9b-CA$2,565,528,258.8820x-5.6x1.2x
Sat, 26 Oct 2024CA$20.0bCA$11.8b-CA$2,717,171,453.5218.4x-7.4x1.7x
Mon, 23 Sep 2024CA$17.8bCA$11.6b-CA$2,695,385,273.3421.3x-6.6x1.5x
Wed, 21 Aug 2024CA$19.8bCA$11.6b-CA$2,736,003,240.3322.4x-7.3x1.7x
Fri, 19 Jul 2024CA$20.6bCA$11.7b-CA$3,191,938,950.4118.9x-6.5x1.8x
Sun, 16 Jun 2024CA$19.3bCA$11.8b-CA$2,769,898,710.4213.2x-7x1.6x
Tue, 14 May 2024CA$24.6bCA$11.9b-CA$3,392,450,017.1414.2x-7.3x2.1x
Thu, 11 Apr 2024CA$25.6bCA$12.0b-CA$3,493,375,864.239.4x-7.3x2.1x
Sat, 09 Mar 2024CA$19.8bCA$11.9b-CA$3,898,781,168.647.5x-5.1x1.7x
Mon, 05 Feb 2024CA$24.8bCA$12.4b-CA$6,728,600,976.009.1x-3.7x2x
Wed, 03 Jan 2024CA$17.7bCA$12.3b-CA$6,728,092,938.009.3x-2.6x1.4x
Fri, 01 Dec 2023CA$17.9bCA$12.4b-CA$6,775,870,288.008.7x-2.6x1.4x
Sun, 29 Oct 2023CA$14.9bCA$12.5b-CA$7,382,124,790.0011x-2x1.2x
Tue, 26 Sep 2023CA$20.3bCA$12.9b-CA$7,879,381,525.0013.9x-2.6x1.6x
Thu, 24 Aug 2023CA$13.9bCA$13.0b-CA$8,056,604,126.0015.5x-1.7x1.1x
Price to Earnings Ratio

-1.7x


Total Market Cap: CA$13.9bTotal Earnings: -CA$8,056,604,126.00Total Revenue: CA$13.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -6.1x202420252026
Current Industry PE
  • Investors are optimistic on the Canadian Pharmaceuticals industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 1.4x is lower than the industry's current PS ratio of 1.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market0.99%
Healthcare-0.92%
Pharma-1.38%
Pharma-1.38%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GTII Green Thumb IndustriesCA$10.054.7%
+CA$98.4m		-5.7%PE12.5x
ACB Aurora CannabisCA$5.1123.1%
+CA$62.3m		-27.0%PS1.1x
CRDL Cardiol TherapeuticsCA$2.5126.1%
+CA$59.9m		37.2%PB12x
VRNO Verano HoldingsCA$8.429.9%
+CA$55.6m		-1.5%PS0.5x
CURA Curaleaf HoldingsCA$13.141.5%
+CA$50.3m		19.0%PS1.9x

Latest News

XLY
CA$3.05
Auxly Cannabis Group
7D
7.0%
1Y
36.2%
Analysis Article • 15h

Revenue Beat: Auxly Cannabis Group Inc. Exceeded Revenue Forecasts By 11% And Analysts Are Updating Their Estimates

It's been a good week for Auxly Cannabis Group Inc. ( TSE:XLY ) shareholders, because the company has just released its...
NVRS
CA$0.22
Noveris Health Sciences
7D
-36.2%
1Y
-56.0%
HLS
CA$3.90
HLS Therapeutics
7D
-3.2%
1Y
-23.2%
Analysis Article • Aug 15

HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

HLS Therapeutics Inc. ( TSE:HLS ) defied analyst predictions to release its quarterly results, which were ahead of...
CRDL
CA$2.51
Cardiol Therapeutics
7D
26.1%
1Y
37.2%
VREO
CA$15.00
Vireo Growth
7D
4.9%
1Y
-49.5%
APTX
CA$34.15
Apotex Health
7D
-8.6%
1Y
n/a
New Narrative • Aug 14

Complex Therapies And New Launches Will Reshape This Generic Drug Maker’s Earnings Profile

Catalysts About Apotex Health Apotex Health develops, manufactures and commercializes generic, specialty and branded medicines across North America and selected international markets. What are the underlying business or industry changes driving this perspective?
ROMJ
CA$0.44
Rubicon Organics
7D
-20.0%
1Y
-18.5%
CPH
CA$14.14
Cipher Pharmaceuticals
7D
-19.4%
1Y
-0.6%
OGI
CA$1.69
Organigram Global
7D
23.4%
1Y
-15.9%
Narrative Update • Aug 13

OGI: Revised Margins And Higher Future P/E Will Shape Earnings Outlook

Analysts have lifted their price target on Organigram Global from CA$1.65 to CA$1.85, citing updated assumptions that include a revised discount rate, a lower projected profit margin, and a higher future P/E multiple. What’s in the News for Organigram Global Organigram Global reaffirmed revenue guidance for fiscal 2026, stating it remains on track for net revenue to exceed $350 million.
ACB
CA$5.11
Aurora Cannabis
7D
23.1%
1Y
-27.0%
CURA
CA$13.14
Curaleaf Holdings
7D
1.5%
1Y
19.0%
VRNO
CA$8.42
Verano Holdings
7D
9.9%
1Y
-1.5%
TSND
CA$0.81
TerrAscend
7D
11.0%
1Y
-31.9%
Narrative Update • Aug 10

TSND: Disciplined M&A And Capital Moves Will Support Future Upside

Analysts have adjusted their fair value estimate for TerrAscend to CA$2.25 from CA$2.01 as they revisit assumptions on revenue growth, profit margins and future P/E expectations. What's in the News for TerrAscend TerrAscend executives reiterated on the second quarter 2026 results call that the company is seeking acquisitions that are accretive and focused on markets where it already has scale and infrastructure, with an emphasis on using existing operations to pursue higher vertical revenue and operating leverage.
GUD
CA$9.32
Knight Therapeutics
7D
-4.5%
1Y
49.8%
GTII
CA$10.05
Green Thumb Industries
7D
4.7%
1Y
-5.7%
Analysis Article • Aug 07

The Green Thumb Industries Inc. (CSE:GTII) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week, you might have seen that Green Thumb Industries Inc. ( CSE:GTII ) released its second-quarter result to the...
MVMD
CA$0.055
Mountain Valley MD Holdings
7D
-31.3%
1Y
175.0%